A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

Ciara Catherine Maria O'Sullivan NCI/NIH, Bethesda, MD info_outline Ciara Catherine Maria O'Sullivan, Karla V. Ballman, Linda Mackie McCall, Tyler J. Zemla, Anna Weiss, Melissa Mitchell, Victoria Susana Blinder, Nadine M. Tung, William Johnson Irvin, Myounghee Lee, Matthew P. Goetz, William Fraser Symmans, Virginia F. Borges, Ian E. Krop, Ann H. Partridge, Lisa A. Carey

Authors Ciara Catherine Maria O'Sullivan NCI/NIH, Bethesda, MD info_outline Ciara Catherine Maria O'Sullivan, Karla V. Ballman, Linda Mackie McCall, Tyler J. Zemla, Anna Weiss, Melissa Mitchell, Victoria Susana Blinder, Nadine M. Tung, William Johnson Irvin, Myounghee Lee, Matthew P. Goetz, William Fraser Symmans, Virginia F. Borges, Ian E. Krop, Ann H. Partridge, Lisa A. Carey Organizations NCI/NIH, Bethesda, MD, Weill Cornell Medicine, New York, NY, Alliance for Clinical Trials in Oncology, Durham, NC, Mayo Clinic, Rochester, MN, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, Memorial Sloan Kettering Cancer Center, New York, NY, Beth Israel Deaconess Medical Center, Boston, MA, University of North Carolina, Midlothian, VA, University of Maryland Medical Center, Baltimore, MD, University of Colorado, Aurora, CO, Dana-Farber Cancer Institute, Boston, MA, University of North Carolina, Chapel Hill, NC Abstract Disclosures Research Funding U.S. National Institutes of Health U.S. National Institutes of Health, Pharmaceutical/Biotech Company, U.S. National Institutes of Health, U24CA196171,U10CA180821, U10CA180882., U.S. National Institutes of Health, Pharmaceutical/Biotech Company, U.S. National Institutes of Health, U24CA196171,U10CA180821, U10CA180882. Background: Patients (pts) with HER2+ early breast cancer (EBC) and invasive residual disease (RD) after neoadjuvant therapy (NAT) have a higher risk of relapse than pts with a pathologic complete response (pCR). Post neoadjuvant T-DM1 has improved invasive disease-free survival (iDFS), but pts with estrogen receptor (ER)-negative or nodal RD have suboptimal outcomes and recurrences in the central nervous system are a problem. More effective treatment strategies are needed. The CompassHER2 trials, EA1181 and A011801, leverage pCR to tailor post neoadjuvant therapy in HER2+ EBC. EA1181 is a NAT de-escalation trial of a taxane, trastuzumab and pertuzumab (THP) in clinical stage II-III HER2+ EBC; pts with a pCR complete HP +/- adjuvant radiation (RT) +/- endocrine therapy (ET). A011801 is an escalation trial for pts with high risk HER2+ RD after NAT, examining addition of the HER2 selective tyrosine kinase inhibitor (TKI) tucatinib to adjuvant T-DM1. Methods: Eligibility and Intervention: Pts. with high-risk HER2+ RD (e.g. ER-,node-positive, or both) after a predefined course of neoadjuvant HER2-directed treatment are randomized 1:1 to adjuvant T-DM1+ placebo (pb), vs. T-DM1 and tucatinib with adjuvant RT +/- ET. Eligibility criteria include completion of ≥ 6 cycles of NAT, including ≥ 9 weeks of T and H +/- P. All chemotherapy (CT) must be completed preoperatively unless participating in EA1181 (̃15-30% enrollees); these pts must receive postoperative CT to complete ≥ 6 cycles prior to enrollment on A011801. Pts who received prior HER2-targeted TKIs or antibody-drug conjugates are ineligible. Objectives: The primary objective is to determine if iDFS is higher with addition of T-DM1 to tucatinib in pts with HER2+ EBC with RD after NAT; secondary endpoints include overall survival, breast cancer free survival, distant recurrence-free survival, brain metastases-free survival and disease-free survival. Correlative objectives include the association of i) tumor infiltrating lymphocyte (TILs) levels in the primary tumor and RD with iDFS, ii) TILs with tucatinib benefit, iii) iDFS and circulating tumor cells (CTC) at serial timepoints and iv) the magnitude of benefit of tucatinib (iDFS) in pts with/without detectable pretreatment CTCs. Quality of life and pharmacokinetic endpoints will also be evaluated. Statistics: A011801 is a prospective, double-blind, randomized, phase III superiority trial; stratified by i) receipt of postoperative CT (Y/N), ii) hormone receptor-status (+/-),and iii) pathologic lymph node status (+/-). The study targets an absolute difference of 5% in iDFS (control vs. experimental arm 82% & 87%, HR = 0.7), with a two-sided alpha of 0.05 and power of 80%. The sample size is 981; target accrual = 1031 pts; activation and completion dates are 01/6/21 and ̃ 01/2028. Support: U10CA180821, U10CA180882; Seagen Inc; ClinicalTrials.gov Identifier: NCT04457596 Clinical trial information: NCT04457596 U.S. National Institutes of Health Pharmaceutical/Biotech Company U.S. National Institutes of Health U24CA196171,U10CA180821, U10CA180882.